Cerebral Venous Thrombosis
17
5
6
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
18%
3 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (17)
Florida Cerebrovascular Disease Biorepository and Genomics Center
Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis
Intracranial Hypertension and Optic Nerve Sheath Diameter
Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam
Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
Philippine Neurological Association One Database - Stroke
Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis
Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis
Clinical Deterioration in Cerebral Venous Thrombosis: A Predictive Study
Study of Rivaroxaban for CeREbral Venous Thrombosis
Efficacy Comparison of Warfarin Versus Rivaroxaban CVT
The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis (CVT)
The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis
Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis
Evaluation of Cerebral Oxygenation and Hemodynamics in Patients With Cerebral Venous Thrombosis
Thrombin Generation and Thrombus Degradation in Cerebral Venous Thrombosis : Clinical and Radiological Correlations